InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
September 26, 2024
NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, today announced that it has executed a broad Memorandum of Understanding (“MoU”) agreement with TheraCour Pharma Inc., an R&D firm, signed on September 23, 2024. As a result, the company has now obtained a right of first refusal (“ROFR”) […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Releases Q2 Financial Report
May 15, 2024
NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, has filed on its second-quarter 2024 financial results for the period ending March 31, 2024; the company filed the report with the U.S. Securities and Exchange Commission on May 14, 2024. Notable numbers from the report include cash and cash equivalent totaling $3.51 million, […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Reports ‘Extremely Significant Results in HV-387 Animal Study Treating RSV
May 14, 2024
NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the antiviral activity of its lead candidate, NV-387, against RSV/A2 is “strong enough to have resulted in full survival of lethally infected animals.” According to the announcement, the company conducted a study that involved extended dosing of NV-387 given orally; those […]
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Exec Participating at Upcoming EF Hutton Global Conference
May 10, 2024
NanoViricides (NYSE American: NNVC) president and executive chair Anil R. Diwan, PhD, will be attending this month’s EF Hutton Annual Global Conference; the event is slated for May 15, 2024, in New York City. NanoViricides is a global leader in broad-spectrum antiviral nanomedicines. The conference provides an opportunity for key executives from public and private […]
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Lead Drug Candidate Indicates Strong Orthopoxvirus Activity
May 8, 2024
NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that, in a lethal animal model, its lead drug candidate, NV-387, showed ultra-broad antiviral activity, including activity against the orthopoxvirus family, including smallpox and mpox. According to the announcement, in the model of lung infection by Ectromelia virus, oral dosing with NV-387 […]
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Reports that NV-387 Shows Strong Activity Against Influenza A
May 6, 2024
NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the ultra-broad antiviral activity spectrum of NV-387 includes influenza A viruses, possibly including bird flu H5N1 virus as well. According to the announcement, the company performed a lethal animal model of lung infection by influenza A/H3N2 virus that indicated NV-387 showed […]
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
May 4, 2023
NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; […]
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
May 4, 2023
SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) — (via IBN) — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which […]
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 3, 2023
NanoViricides (NYSE American: NNVC) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID caused by SARS-CoV-2 coronavirus. NV-CoV-2 is […]